OPKO Health (OPK) to Release Earnings on Thursday

OPKO Health (NASDAQ:OPK) is expected to be releasing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $139.7570 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OPKO Health Stock Performance

Shares of OPK opened at $1.15 on Tuesday. The firm has a market capitalization of $882.86 million, a PE ratio of -4.60 and a beta of 1.47. The company has a quick ratio of 3.32, a current ratio of 3.70 and a debt-to-equity ratio of 0.25. OPKO Health has a 52-week low of $1.11 and a 52-week high of $2.04. The firm has a 50-day moving average price of $1.28 and a 200 day moving average price of $1.36.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on OPK shares. Jefferies Financial Group restated a “hold” rating and set a $1.60 target price (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $2.28.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in OPKO Health by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 67,973 shares in the last quarter. Millennium Management LLC increased its holdings in OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after purchasing an additional 3,600,378 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after buying an additional 1,324,988 shares during the last quarter. Finally, HRT Financial LP acquired a new stake in OPKO Health in the 4th quarter valued at about $851,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.